<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Black Hawk Acquisition Corporation — News on 6ix</title>
    <link>https://6ix.com/company/black-hawk-acquisition-corporation</link>
    <description>Latest news and press releases for Black Hawk Acquisition Corporation on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 08 Jul 2025 01:45:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/black-hawk-acquisition-corporation" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354da878dffbe2df0e609f.webp</url>
      <title>Black Hawk Acquisition Corporation</title>
      <link>https://6ix.com/company/black-hawk-acquisition-corporation</link>
    </image>
    <item>
      <title>Black Hawk Acquisition Corporation Amends Its Definitive Proxy Statement</title>
      <link>https://6ix.com/company/black-hawk-acquisition-corporation/news/black-hawk-acquisition-corporation-amends-014500143</link>
      <guid isPermaLink="true">https://6ix.com/company/black-hawk-acquisition-corporation/news/black-hawk-acquisition-corporation-amends-014500143</guid>
      <pubDate>Tue, 08 Jul 2025 01:45:00 GMT</pubDate>
      <description>DANVILLE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Black Hawk Acquisition Corporation (NASDAQ: BKHAU, the “Company”) announced today that it filed a supplement to its definitive proxy statement, originally filed with the Securities and Exchange Commission on June 10, 2025, to amend the language of the Trust Amendment Proposal. Originally, the Trust Amendment Proposal provided that the Company would deposit into the trust account an amount equal to $0.033 multiplied by the number of ordinary sha</description>
    </item>
    <item>
      <title>Vesicor Therapeutics, Inc. and Black Hawk Acquisition Corporation Enter into a Business Combination Agreement to Create a Biotechnology Company Advancing p53-based Cancer Therapeutics Delivered Via Microvesicles</title>
      <link>https://6ix.com/company/black-hawk-acquisition-corporation/news/vesicor-therapeutics-inc-black-hawk-213000434</link>
      <guid isPermaLink="true">https://6ix.com/company/black-hawk-acquisition-corporation/news/vesicor-therapeutics-inc-black-hawk-213000434</guid>
      <pubDate>Mon, 28 Apr 2025 21:30:00 GMT</pubDate>
      <description>Transaction Values Vesicor at a Pre-money Equity Value of $70 millionBusiness Combination is Expected to be Completed in the Fourth Quarter of 2025 DANVILLE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Black Hawk Acquisition Corp. (Nasdaq: BKHAU, BKHA, BKHAR), a special purpose acquisition company, (“Black Hawk”) announced the signing of a Business Combination Agreement (“BCA”) on April 26, 2025, with Vesicor Therapeutics, Inc. (“Vesicor”, “Vesicor Therapeutics” or “the Company”), a California-ba</description>
    </item>
  </channel>
</rss>